生物免疫疗法联合放疗对小细胞肺癌患者肿瘤标志物及T淋巴细胞亚群水平的影响  

Effect of bioimmunotherapy combined with radiotherapy on tumor markers and T lymphocyte subpopulation level in SCLC patients.

作　　者：李龙 郑振东 刘渤娜 高霄丽 芦洪波 Li Long;Zheng Zhendong;Liu Bona;Gao Xiaoli;Lu Hongbo(Oncology Department, North War Zone General Hospital,Liaoning Provinece,Shenyang 110011, China)

机构地区：[1]北部战区总医院肿瘤科,沈阳110011

出　　处：《疑难病杂志》2021年第3期237-240,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：辽宁省科学技术计划项目(20170540966)。

摘　　要：目的观察生物免疫疗法联合放疗对小细胞肺癌(SCLC)患者肿瘤标志物及T淋巴细胞亚群水平的影响。方法选取2018年12月—2019年12月北部战区总医院肿瘤科治疗小细胞肺癌患者62例,根据随机数字表法分为放疗组、联合治疗组(联合组),每组31例。放疗组患者采取放疗,联合组患者在放疗基础上联合生物免疫疗法。比较2组治疗效果,治疗前后细胞角蛋白19片段抗原(CYFRA21-1)、癌胚抗原(CEA)、血管内皮细胞生长因子受体(VEFGR)、T淋巴细胞亚群变化,并观察不良反应。结果治疗后联合组治疗总有效率为80.65%,高于放疗组的54.84%(χ^(2)=4.723,P=0.029)。与放疗组比较,联合组治疗后,CYFRA21-1、CEA、VEGFR1、VEGFR2、VEGFR3水平均降低(t=6.600、7.286、5.081、16.900、5.005,P均=0.001);联合组CD4^(+)水平升高,CD8+水平降低(t=7.310、7.018,P均=0.001);联合组不良反应发生率低于放疗组(12.90%vs.35.48%,χ^(2)=4.309,P=0.037)。结论通过生物免疫疗法联合放疗对SCLC患者进行治疗,可有效调控肿瘤标志物CYFRA21-1、CEA水平,提高机体免疫能力,有效抑制癌组织生长,治疗效果显著。Objective To explore the effect of bio-immunotherapy combined with radiotherapy on tumor markers and T lymphocyte subsets in SCLC patients.Methods From December 2018 to December 2019,62 patients with small cell lung cancer were treated in the Oncology Department of the North War Zone General Hospital.According to the digital allocation method,they were randomly divided into radiotherapy group and combined treatment group(combined group),with 31 patients in each group.Patients in the radiotherapy group were treated with radiotherapy,while patients in the combination group were treated with bioimmunotherapy on the basis of radiotherapy.The therapeutic effects,cytokeratin 19 fragment antigen(CYFRA21-1),carcinoembryonic antigen(CEA),vascular endothelial growth factor receptor(VEFGR),T lymphocyte subsets and adverse reactions were compared between the two groups.Results The total effective rate of the combined treatment group was 80.65%,54.84%of that of the radiotherapy group(χ^(2)=4.723,P=0.029),after treatment the levels of CYFRA21-1,CEA,VEGFR1,VEGFR2,VEGFR3 were decreased(t=6.600,7.286,5.081,16.900,5.005,P=0.001);the levels of CD4^(+)increased and CD8+decreased in the combined group(t=7.310,7.018,P=0.001);the adverse reaction rate in the combined group was lower than that in the radiotherapy group(12.90%vs.35.48%,χ^(2)=4.309,P=0.037).Conclusion The treatment of SCLC patients by bio-immunotherapy combined with radiotherapy can effectively regulate the levels of tumor markers CYFRA21-1 and CEA,improve the immune capacity of the body,effectively inhibit the growth of cancer tissues,and have significant therapeutic effects.

关 键 词：小细胞肺癌 生物免疫疗法 放射治疗 肿瘤标志物 T淋巴细胞亚群 

分 类 号：R734.2[医药卫生—肿瘤]